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inhibit the expression of HBsAg, HBeAg, and HBV DNA replication
in vitro in a dose-dependent manner. A RT-PCR analysis indicated
that the expression of cccDNA changed signiﬁcantly in the MP
treatment group compared to the control group and in a dose
and time-dependent manner. FK506 did not the same role in
the levels of HBVDNA and cccDNA. However, FK506 at different
nontoxic contrations showed no signiﬁcant inhibitory effect on
the levels of HBsAg HBeAg and HBVDNA.
Conclusion: Our study identiﬁed MP does- and time-dependently
inhibits the HBV replication in vitro, and found that cccDNA for
this inhibitory effect. FK506 does not exercise similar effects.
PP-063 NOTCH 1 regulates FOXP3 regulatory T cells and
deranged TGF-β signaling in progressive stages of
hepatitis B infection
Nirupama TrehanPati *,1, Shikha Shrivastav2, Dinesh
Mani Tripathy2, Sukriti Baweja2, Ketki Dongre2, Hissar Syed2,
Shiv Sarin1,2. 1Institute of Liver and Biliary Sciences, New Delhi,
India; 2G.B. Pant Hospital, New Delhi, India
Objectives: Notch receptors are implicated in modulating the
differentiation of antigen speciﬁc T cells to regulatory T cells.
TGF-β as a key mediator, acts synergistically with regulatory
cells. Our objective was to study the expression of Notch 1,FOXP3
and TGF-β signaling in PBMCs, liver inﬁltrated lymphocytes in pa-
tients with HBV infection.
Methods: Patients with chronic hepatitis B (CHB) (n=10) (age
29.4±13.2 yr., M:F=8:2), HBV cirrhosis (n=8) (age-45.6±12 yr.
M:F=2:1) and liver biopsies from normal liver (n=8) (age 49±3.8
yr. M:F=3:1) were studied. PBMCs and LIL were isolated from
blood and liver tissues. Percentages of regulatory T cells with
Notch expression were analyzed by FACS Analysis. mRNA expres-
sion of Notch1, HES1, Jagged1, TGF-β, STAT1, SMAD3 and SMAD4
genes was analyzed by quantitative RT-PCR in PBMCs, LIL and
biopsies.
Results: There was a signiﬁcantly higher co-expression of Notch1
and the percentages of NOTCH1/FOXP3 (50.4% vs.3.72 and 2%)
(p=0.05) in liver inﬁltrated lymphocytes of cirrhotic patients than
peripheral blood. Expression of TGF-β, STAT1, SMAD3 and SMAD4
in cirrhotic LIL was signiﬁcantly 2-3 folds lower than PBMCs. In
chronic HBV biopsies, expression of TGF-β, STAT1, SMAD3 and
SMAD4 was 4-6 folds higher than in normal liver biopsies.
Conclusion: We showed that higher expression of Notch1 and
FOXP3 expression in liver inﬁltrated lymphocytes may have
differentiated induced regulatory T cells. However, decreased
expression of TGF-β and its downstream signaling molecules in
LILs may be responsible for loss of its regulatory cells suppressive
ability.
PP-064 A tenofovir therapy HBV mathematical model for
HBeAg negative and positive patient
Man Li, Yongmei Su*. Applied Science School, University of
Science and Technology Beijing, Beijing
Background: HBeAg negative and HBeAg positive patients are
different in the HBV replication rate. Based on P.Marcellin et al’s
clinical data and the HBV infection dynamic model proposed by
Nowak et al. we set up a Tenofovir therapy model for HBeAg
negative and positive, which have good agreement with above
clinical data.
Methods: A model of HBV is described by four variables: x, y,
v, z represent uninfected cells, infected cells, free virus, and
immune cells. The model include 10 parameters: λ, d, b, a, p, k,
u, k2, k3, k4 where the meanings of λ, d, b, a, p, k, u are the
same as those given in Nowak’s model, k2 represents the curative
effect, k3, k4 are relevant to the immune, we choose {λ, d, b,
a, p, u, k3, k4 = 4.621e5, 6.9e-3, 6.508e-4, 6.9e-3, 0.058, 0.35,
0.95, 0.036}
For HBeAg positive and negative, we chose k=5, k2=4.85, and k=2,
k2=1.98 respectively, which reﬂect the different HBV replication
rate between HBeAg positive and negative patient.
Results: The simulation data of our model are qualitatively
agreement with the HBeAg positive and negative clinical data
during the treatment with Tenofovir.
Conclusion: The discrepancy between HBeAg negative and posi-
tive were reﬂected through different parameters by our model,
which shows our model may possibly capture the dynamics of
anti-HBV infection treatment with Tenofovir.
Acknowledgment: This work is jointly supported by the11-5 Key
Special Project of China (No. 2008ZX10502) and the NNSF of
China (No. 0674059).
PP-065 Therapeutical effect of Ademetionine
(Transmetil) for chronic cholestasis diseases
Wen Xie*, Yan-Bin Wang, Wei-Ni Ou. Beijing Ditan Hospital
Objective: To evaluate the efﬁcacy and safety of different
dosage of Ademetionine (Transmetil) in different cholestasis
diseases.
Methods: It’s a retrospective study, 56 cases who treated with
Ademetionine (Transmetil) were assigned to 1g/d and 2g/d by
the dosage they used. There is no statistic difference between
the two groups in age, height, body weight, heart rate, blood
pressure and sex ratio (P>0.05). The levels of ALT, AST, TBiL,
DBiL, GGT and TBA before treated and 2 weeks after treated of
both groups were observed.
Results: After 2 wk of treatment, the levels of ALT, AST, TBiL,
DBiL, GGT and TBA were reduced signiﬁcantly (p=0.001, 0.002,
0.029, 0.01, 0.002, 0.002 P<0.05) compared with those before
treatment, but the reduced levels of ALT, AST and GGT had no
marked difference between the two groups (p=0.055, 0.14, 0.774
P>0.05). And the reduced levels of TBiL, DBiL and TBA were
signiﬁcantly different between the two groups (p=0.025, 0.038,
0.039 P<0.05). No severe adverse reactions were found in both
groups.
Conclusions: Ademetionine (Transmetil) has obvious effect on
Cholestasis diseases, and the treatment of dosage 2g/d has more
effective in reduce TBiL, DBiL and TBA than that of 1g/d. It’s
safe in both dosage groups.
PP-066 Effect of adeforvir dipivoxil on HBcAg-speciﬁc
cytotoxic T cells in patients with chronic
hepatitis B
Jie Yan1, Wen Xie*,1, Yahui Lin2, Xin Feng1, Beibei Wang1,
Jiang Xiao1, Weini Ou1, Yangbin Wang1, Jun Cheng1. 1Beijing
Ditan Hospital; 2Chinese Academy of Medical Sciences
Background:To study the effect of adeforvir dipivoxil on HBcAg-
speciﬁc cytotoxic T cells in patients with chronic hepatitis B
(CHB).
Methods: Frequency of circulating HBcAg-speciﬁc cytotoxic T
cells from 11 HLA-A2+ patients with chronic hepatitis B were
studied longitudinally before and after adeforvir dipivoxil ther-
apy by HLA-A2/peptide tetramer staining.
Results: Frequencies of HBcAg-speciﬁc cytotoxic T cells were
no signiﬁcant differences between before and after adeforvir
dipivoxil therapy.
Conclusion: There is probably no effect effect of adeforvir
dipivoxil on HBcAg-speciﬁc cytotoxic T cells in patients with CHB.
PP-067 Effects of interventional therapy for primary liver
carcinoma on the liver function of patients
Wei Ji *. Beijing You-an Hospital
Background: The effects of interventional therapy for hepato-
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cellular carcinoma (HCC) on the liver function of the patients
were analyzed.
Methods: The patients’ liver function were assessed according to
Child-Pugh criteria before and after the therapy.
Results: The numbers of the patients with Child A, Child B and
Child C were 181, 52 and 6 before interventional therapy for
HCC, and 132, 82 and 25 after the therapy (P<0.01). The number
of the patients with Child A decreased and that of the patients
with Child B and Child C increased, but the liver function of
some of the patients with Child B and Child C transformed into
Child A or Child B after the two weeks of the therapy. Analysis
of the patients whose serum levels of total bilirubin (Tbil) and
aspartate aminotransferase (AST) were above 50umol/L and 120
U/L, and whose serum levels of albumin (ALB) and acetylcholine
esterase (CHE) were below 25g/L and 1500 U/L showed that
there was no notably changing of the levels of these marks after
the therapy (P>0.05). Compared to the patients with Child B
and Child C, the patients with Child A had higher levels of Tbil
and AST and lower levels of ALB and CHE after the therapy than
before (P<0.01).
Conclusions: The interventional therapy for HCC had worse
effects on the liver function of the patients, but carefully pro-
tecting the liver function by medicine treatment before and after
the interventional therapy will reduce the effects.
PP-068 Dolichol in urine might serve as a laboratory
marker of drug resistance in HBV
Galina Kuznecova*, Sergejs Kuznecovs. Cancer Research
Laboratory
Background: Dolichyl (Dol), the main lipid intermediator of
Dolichyl Phosphate Cycle (DPC) has been reported to be elevated
in urine of patients with multidrug resistance in cancer. Drug
resistance poses a major threat to nucleoside analogue-based
therapies for chronic HBV infection.
Methods: With focus on a marker for susceptibility to the de-
velopment of HBV drug resistance the study was carried out to
estimate urinary Dol in patients with chronic HBV infection. The
samples obtained every week before and during the course of
treatment from 42 patients with HBV. The occurrence of exacer-
bations of chronic HBV were registered for 2 years. Dol in urine
was assayed by HPLC method (Turpeinen, 1986).
Result: The normal amounts of Dol in healthy persons urine
(n=1500) are 6,0±10,0 mkg/mmol creatine. During the period
of observation 36 (86%) of patients treated with nucleoside
analogue-based therapies were diagnosed with exacerbations
due to resistance of hepatitis B virus to antiviral drugs. From
this group of HBV patients 35 (98%) have had elevated urinal Dol
excreation (45,8±5,2 μg/ml vs. 8,2±1,9 μg/ml, p<0.0001) in
more than 3 months of observation.
Conclusion: There is a reason to suggest that elevated urinal Dol
detected in patients with exacerbations during HBV treatment
may evidence of possible defect of host mechanism of drug
resistance development to nucleoside analogue-based therapies.
The interest drawn to the employment of Dol as a predictor for
exacerbation of chronic HBV is explained by the role of DPC in
P-glycoprotein regulation in human hepatocytes.
PP-069 The molecular mechanism of HBc downregulating
DR5 expression
Juan Du*,1, Xiaohong Liang2, Lili Cao1, Jie Li 1, Jingjie Sun1,
Wensheng Sun2. 1Central laboratory of Shandong Qianfoshan
Hospital; 2Institute of Immunology, School of Medicine,
Shandong University
Background:We have found, for the ﬁrstly, that HBV core protein
(HBc) downregulated DR5 expression. But the mechanism is not
clear. The purpose of the study is to probe the molecular mech-
anism though which HBc downregulated TRAIL death receptor 2
(DR5) expression.
Methods: Western blot and Dual-luciferas assay were used to
detect the DR5 expression and the DR5 promoter activity with or
without HBc expression. Oligonucleotide chip assay to screening
the Differentially Expressed Genes after HBc transfection. Real-
time PCR and Western blot to verify the Differentially Expressed
Genes.
Result: HBc decreased the expression of DR5. The further study
showed HBc signiﬁcantly repressed the promoter activity of the
human DR5 gene. To further explore the mechanism how HBc
affects DR5 promoter, we examed the microarray chip assay.The
microarray analysis indicated that HBc also represses P53 ex-
pression. Recently, Researchers have found that P53 can affect
DR5 promoter activity. Whether the HBc-p53 pathway plays a
signiﬁcant role in regulating DR5 expression needs to be further
studied.
Conclusion: Our results establish that HBc may decrease DR5 ex-
pression though impairing P53 expression. Additionally, HBc may
prevent hepatocytes from TRAIL-induced apoptosis by blocking
DR5 expression, which in turn contributes to the development of
chronic hepatitis and HCC.
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PP-070 Infants non- and low-response after recombinant
yeast derived hepatitis B vaccinated and
inﬂuencing factors analysis
Hui Zheng*, Fu-zhen Wang, Yuansheng Chen. Chinese Center for
Disease Control and Prevention
Objective: To understand the non-and-lowresponse of infants af-
ter recombinant yeast derived hepatitis B vaccinated and analysis
the inﬂuencing factors.
Methods: 2788 infants born during 2004-2005 were vaccinated
with 5μg×3 hepatitis B vaccinated by 0,1,6 months schedule. The
seromarks (HBsAg, anti-HBs, anti-HBc) were detected by RIA, and
collected some information from the parents by questionnaires.
Results: After three doses; the min- titres of anti-HBs was 0.18
mIU/ml, the max -titres was 19736.00 mIU/ml, the GMC was
264.33 mIU/ml. The percentage of Non- and low-responseWAS
16.89%, with non-response was 1.72% and low-response is 15.17%,
in which, males’ was higher than female, premature was higher
than mature, low-birthweight infants was higher than normal.
but no statistic differents were seen (p>0.05).
Conclusions: Non-and-lowresponse of infant after hepatitis B
vaccinated was 16.89%, and the non-respose was 1.72%. No
effects of the gender, abortion and birth-weight were observed.
PP-071 Evaluation of the impact of hepatitis B
vaccination among children born between 1992
and 2005 in China
Fuqiang Cui *. Chinese Center for Disease Control and Prevention
Background: Endemic hepatitis B virus (HBV) infection is a seri-
ous health problem in China. Hepatitis B vaccination of infants
was introduced in 1992, and progressively expanded during the
subsequent 15 years.
Methods: National serosurvey, with participants selected by
multi-stage random sampling. Demographics and hepatitis B
vaccination history collected by questionnaire and review of
vaccination records, and serum tested for hepatitis B surface
antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc)
and hepatitis B surface antibody (anti-HBs) by ELISA.
Results: Hepatitis B vaccine coverage (3 doses) increased from
30.0% for children born in 1992 to 93.4% for children born
in 2005. Timely birth dose increased from 22.2% to 82.6% for
